{"id":"https://openalex.org/W3202686230","doi":"https://doi.org/10.1182/bloodadvances.2021005304","title":"Adoptive T-cell therapy for Hodgkin lymphoma","display_name":"Adoptive T-cell therapy for Hodgkin lymphoma","publication_year":2021,"publication_date":"2021-10-06","ids":{"openalex":"https://openalex.org/W3202686230","doi":"https://doi.org/10.1182/bloodadvances.2021005304","mag":"3202686230","pmid":"https://pubmed.ncbi.nlm.nih.gov/34610100","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8945637"},"language":"en","primary_location":{"id":"doi:10.1182/bloodadvances.2021005304","doi":"https://doi.org/10.1182/bloodadvances.2021005304","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2021005304","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/5/20/4291/1830445/advancesadv2021005304.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://ashpublications.org/bloodadvances/article-pdf/5/20/4291/1830445/advancesadv2021005304.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088009215","display_name":"Carrie Ho","orcid":"https://orcid.org/0000-0003-4437-9377","observed_orcids":["https://orcid.org/0000-0003-4437-9377"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carrie Ho","raw_affiliation_strings":["Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and"],"raw_orcid":"https://orcid.org/0000-0003-4437-9377","affiliations":[{"raw_affiliation_string":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088355904","display_name":"Marco Ruella","orcid":"https://orcid.org/0000-0003-4301-5811","observed_orcids":["https://orcid.org/0000-0003-4301-5811"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marco Ruella","raw_affiliation_strings":["Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA","Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029979708","display_name":"Bruce L. Levine","orcid":"https://orcid.org/0000-0001-6971-8465","observed_orcids":["https://orcid.org/0000-0001-6971-8465"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce L. Levine","raw_affiliation_strings":["Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA","Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and"],"raw_orcid":"https://orcid.org/0000-0001-6971-8465","affiliations":[{"raw_affiliation_string":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I79576946"]},{"raw_affiliation_string":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005058090","display_name":"Jakub Svoboda","orcid":"https://orcid.org/0000-0002-6359-7065","observed_orcids":["https://orcid.org/0000-0002-6359-7065"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jakub Svoboda","raw_affiliation_strings":["Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5005058090"],"corresponding_institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":1.4366,"has_fulltext":true,"cited_by_count":21,"citation_normalized_percentile":{"value":0.85800812,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"5","issue":"20","first_page":"4291","last_page":"4302"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/classical-hodgkin-lymphoma","display_name":"classical Hodgkin lymphoma","score":0.8700000047683716},{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.9700000286102295},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.9750000238418579},{"id":"https://openalex.org/keywords/cd30","display_name":"CD30","score":0.8259999752044678},{"id":"https://openalex.org/keywords/cd19","display_name":"CD19","score":0.9789999723434448},{"id":"https://openalex.org/keywords/cd123","display_name":"CD123","score":1.0},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.8529999852180481},{"id":"https://openalex.org/keywords/clinical-trials","display_name":"clinical trials","score":0.621999979019165},{"id":"https://openalex.org/keywords/immunotherapy-development","display_name":"immunotherapy development","score":0.5849999785423279}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6703910231590271},{"id":"https://openalex.org/C10882517","wikidata":"https://www.wikidata.org/wiki/Q15268054","display_name":"Cell therapy","level":3,"score":0.6414401531219482},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6256301999092102},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5921210646629333},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5734272003173828},{"id":"https://openalex.org/C90375314","wikidata":"https://www.wikidata.org/wiki/Q3537484","display_name":"Adoptive cell transfer","level":4,"score":0.5639106035232544},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5554385185241699},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.5413496494293213},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.46273717284202576},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45527783036231995},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3779773712158203},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3657929301261902},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.28276681900024414},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2767331004142761},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.27634942531585693},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18433204293251038},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D004854","descriptor_name":"Herpesvirus 4, Human","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006689","descriptor_name":"Hodgkin Disease","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016219","descriptor_name":"Immunotherapy, Adoptive","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020031","descriptor_name":"Epstein-Barr Virus Infections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D059016","descriptor_name":"Tumor Microenvironment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064987","descriptor_name":"Cell- and Tissue-Based Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1182/bloodadvances.2021005304","doi":"https://doi.org/10.1182/bloodadvances.2021005304","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2021005304","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/5/20/4291/1830445/advancesadv2021005304.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8945637","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8945637","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Adv","raw_type":"Text"},{"id":"pmid:34610100","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34610100","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood advances","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1182/bloodadvances.2021005304","doi":"https://doi.org/10.1182/bloodadvances.2021005304","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2021005304","pdf_url":"https://ashpublications.org/bloodadvances/article-pdf/5/20/4291/1830445/advancesadv2021005304.pdf","source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1472606672","display_name":"Resistance To Targeted Immunotherapies:CART19 as a Paradigm","funder_award_id":"K99CA212302","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G1527440055","display_name":"Resistance To Targeted Immunotherapies:CART19 as a Paradigm","funder_award_id":"R00CA212302","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000904249","display_name":"Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19","funder_award_id":"P01CA214278","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3202686230.pdf","grobid_xml":"https://content.openalex.org/works/W3202686230.grobid-xml"},"referenced_works_count":68,"referenced_works":["https://openalex.org/W151068973","https://openalex.org/W1495792176","https://openalex.org/W1545631997","https://openalex.org/W1972168709","https://openalex.org/W1976133526","https://openalex.org/W1978290302","https://openalex.org/W1986354050","https://openalex.org/W1993732758","https://openalex.org/W1997987267","https://openalex.org/W2009709218","https://openalex.org/W2011118089","https://openalex.org/W2013229326","https://openalex.org/W2018561279","https://openalex.org/W2027293043","https://openalex.org/W2034400622","https://openalex.org/W2050937173","https://openalex.org/W2051830227","https://openalex.org/W2057925735","https://openalex.org/W2062486240","https://openalex.org/W2067948267","https://openalex.org/W2069720281","https://openalex.org/W2071518796","https://openalex.org/W2071949698","https://openalex.org/W2076668490","https://openalex.org/W2094798767","https://openalex.org/W2107317733","https://openalex.org/W2120020619","https://openalex.org/W2125616358","https://openalex.org/W2130338247","https://openalex.org/W2131636403","https://openalex.org/W2132836791","https://openalex.org/W2140801657","https://openalex.org/W2162848902","https://openalex.org/W2163062545","https://openalex.org/W2164900174","https://openalex.org/W2168937900","https://openalex.org/W2169329800","https://openalex.org/W2171741398","https://openalex.org/W2337659275","https://openalex.org/W2408893420","https://openalex.org/W2500482667","https://openalex.org/W2513177163","https://openalex.org/W2515679023","https://openalex.org/W2531617746","https://openalex.org/W2591946624","https://openalex.org/W2620723923","https://openalex.org/W2743083943","https://openalex.org/W2752993654","https://openalex.org/W2753945613","https://openalex.org/W2755078225","https://openalex.org/W2773804840","https://openalex.org/W2775803967","https://openalex.org/W2783925321","https://openalex.org/W2792588868","https://openalex.org/W2802394123","https://openalex.org/W2807947863","https://openalex.org/W2809520091","https://openalex.org/W2864786814","https://openalex.org/W2889641854","https://openalex.org/W2892410396","https://openalex.org/W2898963257","https://openalex.org/W2980642079","https://openalex.org/W2994693426","https://openalex.org/W2995900562","https://openalex.org/W3004461655","https://openalex.org/W3044350523","https://openalex.org/W4252401126","https://openalex.org/W6769081400"],"related_works":["https://openalex.org/W4416930946","https://openalex.org/W1980888421","https://openalex.org/W2559013124","https://openalex.org/W2983354402","https://openalex.org/W2776677617","https://openalex.org/W2980273656","https://openalex.org/W1543423342","https://openalex.org/W4220844749","https://openalex.org/W4410593961","https://openalex.org/W2516040314"],"abstract_inverted_index":{"Although":[0],"CAR":[1,45,65,109],"T-cell":[2,35,110],"therapy":[3,36,111],"is":[4],"US":[5],"Food":[6],"and":[7,43,63,101],"Drug":[8],"Administration-approved":[9],"for":[10,19,91,112],"B-cell":[11],"non-Hodgkin":[12],"lymphomas,":[13],"the":[14,20,70,83,106],"development":[15,107],"of":[16,22,57,85,88,108],"adoptive":[17,89],"immunotherapy":[18,90],"treatment":[21],"classic":[23],"Hodgkin":[24],"lymphoma":[25],"(cHL)":[26],"has":[27],"not":[28],"accelerated":[29],"at":[30],"a":[31,96],"similar":[32],"pace.":[33],"Adoptive":[34],"with":[37,59,93,95],"Epstein-Barr":[38],"virus-specific":[39],"cytotoxic":[40],"T":[41,46,66],"lymphocytes":[42],"CD30":[44],"cells":[47,67],"have":[48,76],"demonstrated":[49],"significant":[50],"clinical":[51,55,86],"responses":[52],"in":[53,74],"early":[54],"trials":[56,87],"patients":[58,92],"cHL.":[60,113],"Additionally,":[61],"CD19":[62],"CD123":[64],"that":[68],"target":[69],"immunosuppressive":[71],"tumor":[72],"microenvironment":[73],"cHL":[75,94],"also":[77],"been":[78],"investigated.":[79],"Here":[80],"we":[81],"discuss":[82],"landscape":[84],"view":[97],"toward":[98],"current":[99],"challenges":[100],"novel":[102],"strategies":[103],"to":[104],"improve":[105]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-10-11T00:00:00"}